Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Open in Screener

IVVD

Invivyd Inc

Nov 20 • 04:00PM ET

2.40

-0.10 -4.00 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX MRK JNJ NVAX AZN GSK GILD SNY

| Held by: VTI VXF PRFZ AVSC

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	19.99%	Shs Outstand	214.41M	Perf Week	35.59%
Market Cap	559.50M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	-0.49%	Shs Float	186.52M	Perf Month	29.03%
Enterprise Value	477.21M	PEG	-	EPS next Q	-0.09	Inst Own	70.52%	Short Float	12.93%	Perf Quarter	361.45%
Income	-59.86M	P/S	11.18	EPS this Y	71.79%	Inst Trans	17.36%	Short Ratio	2.30	Perf Half Y	215.58%
Sales	50.04M	P/B	5.53	EPS next Y	50.41%	ROA	-39.76%	Short Interest	24.13M	Perf YTD	441.64%
Book/sh	0.43	P/C	6.58	EPS next 5Y	55.04%	ROE	-67.94%	52W High	3.07 -21.82%	Perf Year	224.32%
Cash/sh	0.36	P/FCF	-	EPS past 3/5Y	11.20% -24.99%	ROIC	-63.24%	52W Low	0.35 576.82%	Perf 3Y	-31.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	86.97%	Volatility	17.66% 13.78%	Perf 5Y	-
Dividend TTM	-	EV/Sales	9.54	EPS Y/Y TTM	75.73%	Oper. Margin	-124.37%	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.46	Sales Y/Y TTM	332.71%	Profit Margin	-119.63%	RSI (14)	61.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.47	EPS Q/Q	87.90%	SMA20	22.68%	Beta	0.50	Target Price	7.33
Payout	-	Debt/Eq	0.03	Sales Q/Q	41.17%	SMA50	44.07%	Rel Volume	0.46	Prev Close	2.50
Employees	99	LT Debt/Eq	0.02	Earnings	Nov 06 BMO	SMA200	129.61%	Avg Volume	10.48M	Price	2.40
IPO	Aug 06, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.00% 0.24%	Trades		Volume	4,800,461	Change	-4.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Nov-17-25 10:40PM	Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +20.85% -10.92%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-06-25 09:15AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:52AM	Invivyd Inc (IVVD) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com) +8.57%
07:40AM	Loading…
07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) -13.04%
Nov-03-25 04:01PM	Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025 (GlobeNewswire) -8.52%
Oct-28-25 07:01AM	Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Oct-06-25 07:01AM	Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire) +22.41%
Sep-24-25 04:01PM	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors (GlobeNewswire) +5.17% -6.56%
Sep-23-25 07:25PM	Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval (Insider Monkey)
Sep-17-25 07:01AM	Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer (GlobeNewswire) -8.73%
Sep-04-25 07:01AM	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 (GlobeNewswire)
Aug-27-25 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.44%
10:30AM	Loading…
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +84.03%
Aug-22-25 12:00PM	Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-25 11:58PM	Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +11.00% -16.71%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-18-25 04:32PM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") (GlobeNewswire) -17.82%
Aug-14-25 06:00PM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.54%
04:49PM	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
04:47PM	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 (GlobeNewswire)
Aug-12-25 05:40PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-08-25 05:30AM	The Race to Find a Measles Treatment as Infections Surge (The Wall Street Journal) +5.88%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.10%
Aug-06-25 08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-23-25 07:01AM	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire) +5.26%
Jul-21-25 07:05AM	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population (GlobeNewswire)
Jul-02-25 07:01AM	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire)
07:01AM	Loading…
Jun-26-25 07:01AM	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection (GlobeNewswire) +13.43%
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-29-25 02:36PM	H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall (Insider Monkey)
May-27-25 07:01AM	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus (GlobeNewswire) +20.15%
May-23-25 07:01AM	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas (GlobeNewswire)
May-21-25 09:30AM	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 (GlobeNewswire) -5.52%
May-16-25 03:08AM	Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ... (GuruFocus.com) +10.33%
01:57AM	Q1 2025 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 08:15AM	Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -15.78%
07:01AM	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-14-25 09:53AM	What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings (GuruFocus.com)
07:01AM	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy (GlobeNewswire)
May-13-25 07:01AM	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-12-25 07:01AM	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles (GlobeNewswire) +29.67%
May-08-25 07:01AM	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
Apr-21-25 09:58AM	What's Going On With Invivyd Stock On Monday? (Benzinga) +10.00%
07:01AM	Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank (GlobeNewswire)
Mar-26-25 04:15PM	Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors (GlobeNewswire) -6.70%
Mar-20-25 09:25AM	Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-12-25 09:40AM	Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? (Zacks)
Mar-05-25 07:05AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 (GlobeNewswire)
Mar-02-25 11:32AM	Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 12:12PM	Adagio Medical cuts workforce and pauses cryo catheter launch in EU (Medical Device Network) -6.45%
Feb-24-25 07:05AM	FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -29.94%
Feb-18-25 10:27AM	Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far (Insider Monkey) -9.32%
Feb-10-25 07:00AM	Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 (GlobeNewswire) -23.04%
Feb-05-25 09:30AM	Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold (GlobeNewswire) +68.80%
Feb-03-25 07:20PM	Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025 (Insider Monkey) +196.34% +17.92%
07:00AM	Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population (GlobeNewswire)
06:55AM	Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability (GlobeNewswire)
Jan-27-25 07:01AM	Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -12.85%
Jan-10-25 12:12PM	What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday? (Benzinga)
07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC (GlobeNewswire)
Jan-07-25 09:34AM	Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-17-24 06:25AM	Adagio Medical announces Todd Usen as new CEO and director (Medical Device Network) +8.77%
Nov-15-24 03:17AM	Q3 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... (GuruFocus.com)
Nov-14-24 08:20AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.18%
07:05AM	Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
07:01AM	Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor (GlobeNewswire)
Nov-13-24 07:27AM	Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com) -11.00%
Nov-12-24 08:30AM	Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively (GlobeNewswire)
Nov-06-24 08:01AM	Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire) +12.62%
07:01AM	Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 (GlobeNewswire)
Oct-29-24 07:03AM	Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability (GlobeNewswire) -12.80%
07:01AM	Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants (GlobeNewswire)
Oct-16-24 07:01AM	Invivyd to Present PEMGARDA (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 (GlobeNewswire)
Oct-01-24 07:01AM	Invivyd Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data (GlobeNewswire) -11.75%
Sep-23-24 07:01AM	Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA (pemivibart) (GlobeNewswire)
Sep-12-24 07:01AM	Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 (GlobeNewswire) +12.75%
Sep-05-24 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-04-24 07:01AM	Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA (GlobeNewswire)
Sep-03-24 07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest (GlobeNewswire)
Aug-27-24 07:01AM	Invivyd Announces PEMGARDA (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial (GlobeNewswire) -28.67%
Aug-15-24 02:43AM	Q2 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) +6.12%
Aug-14-24 09:10AM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.55%
08:01AM	Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-12-24 04:01PM	Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -6.31% +9.84%
Jul-01-24 07:01AM	Invivyd Announces its Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) +9.09%
Jun-14-24 07:01AM	Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants (GlobeNewswire) -7.06%
Jun-03-24 04:01PM	Invivyd to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-31-24 07:05AM	Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies (GlobeNewswire)
07:00AM	Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer (GlobeNewswire)
May-29-24 07:00AM	Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC) (GlobeNewswire)
May-22-24 07:00AM	Invivyd Elects Two New Independent Members to its Board of Directors (GlobeNewswire)
May-13-24 04:01PM	Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
10:44AM	Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:25PM	Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com) -6.61%
May-09-24 10:56PM	IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024 (InvestorPlace)

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCLAUGHLIN KEVIN F	Director	Nov 19 '25	Buy	2.50	50,000	125,000	50,000	Nov 20 04:22 PM
ADIMAB, LLC	10% Owner	Nov 17 '25	Proposed Sale	3.00	1,233,416	3,703,455		Nov 17 04:36 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	59,344	Aug 19 09:28 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	88,987	Aug 19 09:28 PM
Duke William E.	Chief Financial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:25 PM
Duke William E.	Chief Financial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:25 PM
Green Julie	Chief Human Resources Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:24 PM
Green Julie	Chief Human Resources Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:24 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 19 '25	Sale	0.57	49,402	27,991	84,446	Aug 19 09:21 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 18 '25	Sale	0.65	33,352	21,685	133,848	Aug 19 09:21 PM
Allen Robert D. III	Chief Scientific Officer	Aug 19 '25	Sale	0.57	27,420	15,536	53,068	Aug 19 09:20 PM
Allen Robert D. III	Chief Scientific Officer	Aug 18 '25	Sale	0.65	18,512	12,037	80,488	Aug 19 09:20 PM
Green Julie	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:55 PM
Andersen Jill	Officer	Aug 18 '25	Proposed Sale	0.71	66,000	46,669		Aug 18 06:54 PM
Allen Robert D. III	Officer	Aug 18 '25	Proposed Sale	0.71	36,631	25,902		Aug 18 06:53 PM
Lee Timothy Edward	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:49 PM
Duke William E.	Officer	Aug 18 '25	Proposed Sale	0.71	39,601	28,002		Aug 18 06:44 PM
MCGUIRE TERRANCE	Director	Dec 31 '24	Sale	0.45	103,474	46,098	3,066,757	Dec 31 07:16 PM
MCGUIRE TERRANCE	Director	Dec 27 '24	Sale	0.52	83,744	43,647	3,256,776	Dec 31 07:16 PM
MCGUIRE TERRANCE	Director	Dec 30 '24	Sale	0.48	86,545	41,784	3,170,231	Dec 31 07:16 PM
MCGUIRE TERRANCE	Director	Dec 20 '24	Sale	0.42	119,805	50,725	3,568,274	Dec 26 07:46 PM
MCGUIRE TERRANCE	Director	Dec 26 '24	Sale	0.54	83,817	45,563	3,340,520	Dec 26 07:46 PM
MCGUIRE TERRANCE	Director	Dec 24 '24	Sale	0.51	68,161	34,503	3,424,337	Dec 26 07:46 PM
MCGUIRE TERRANCE	Director	Dec 23 '24	Sale	0.45	75,776	34,076	3,492,498	Dec 26 07:46 PM
POLARIS PARTNERS IX, LP	Director	Dec 20 '24	Proposed Sale	0.44	1,000,000	443,900		Dec 20 04:46 PM
MCGUIRE TERRANCE	Director	Dec 19 '24	Sale	0.43	152,067	65,951	3,688,079	Dec 19 05:54 PM
MCGUIRE TERRANCE	Director	Dec 17 '24	Sale	0.48	97,410	46,757	3,914,910	Dec 19 05:54 PM
MCGUIRE TERRANCE	Director	Dec 18 '24	Sale	0.47	74,764	35,087	3,840,146	Dec 19 05:54 PM
MCGUIRE TERRANCE	Director	Dec 12 '24	Sale	0.58	125,000	72,875	4,077,679	Dec 16 08:29 PM
MCGUIRE TERRANCE	Director	Dec 16 '24	Sale	0.47	65,359	30,510	4,012,320	Dec 16 08:29 PM
MCGUIRE TERRANCE	Director	Dec 10 '24	Sale	0.59	175,000	103,005	4,363,079	Dec 11 06:26 PM
MCGUIRE TERRANCE	Director	Dec 11 '24	Sale	0.59	160,400	94,812	4,202,679	Dec 11 06:26 PM
MCGUIRE TERRANCE	Director	Dec 09 '24	Sale	0.61	150,000	91,560	4,538,079	Dec 11 06:26 PM
POLARIS PARTNERS IX, LP	Director	Dec 09 '24	Proposed Sale	0.61	1,000,000	610,400		Dec 09 04:27 PM

Open in Screener

VCEL

Vericel Corp

Nov 20 • 04:00PM ET

37.85

-1.10 -2.82 %

Healthcare • Biotechnology • USA • NASD

Peers: MDXG ATRC OFIX PODD RVNC ICUI HAE APYX CUTR ENZ

| Held by: IJR VTI IWM XBI VXF IWO SPSM IJT IBB SLYG

Index	RUT	P/E	157.18	EPS (ttm)	0.24	Insider Own	1.11%	Shs Outstand	50.55M	Perf Week	-4.99%
Market Cap	1.91B	Forward P/E	66.36	EPS next Y	0.57	Insider Trans	-7.27%	Shs Float	50.01M	Perf Month	3.90%
Enterprise Value	1.88B	PEG	2.33	EPS next Q	0.39	Inst Own	105.57%	Short Float	8.89%	Perf Quarter	2.21%
Income	13.08M	P/S	7.40	EPS this Y	34.40%	Inst Trans	-1.71%	Short Ratio	6.16	Perf Half Y	-8.53%
Sales	258.72M	P/B	5.94	EPS next Y	112.18%	ROA	3.10%	Short Interest	4.44M	Perf YTD	-31.07%
Book/sh	6.37	P/C	14.14	EPS next 5Y	67.41%	ROE	4.52%	52W High	63.00 -39.92%	Perf Year	-28.44%
Cash/sh	2.68	P/FCF	93.93	EPS past 3/5Y	- -	ROIC	3.21%	52W Low	29.24 29.45%	Perf 3Y	62.59%
Dividend Est.	-	EV/EBITDA	110.25	Sales past 3/5Y	14.95% 15.02%	Gross Margin	73.81%	Volatility	4.08% 4.68%	Perf 5Y	46.76%
Dividend TTM	-	EV/Sales	7.26	EPS Y/Y TTM	241.86%	Oper. Margin	2.75%	ATR (14)	1.77	Perf 10Y	1831.12%
Dividend Ex-Date	-	Quick Ratio	4.47	Sales Y/Y TTM	14.05%	Profit Margin	5.06%	RSI (14)	52.48	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.87	EPS Q/Q	631.52%	SMA20	-0.05%	Beta	1.17	Target Price	55.71
Payout	0.00%	Debt/Eq	0.31	Sales Q/Q	16.58%	SMA50	8.67%	Rel Volume	0.56	Prev Close	38.95
Employees	357	LT Debt/Eq	0.27	Earnings	Nov 06 BMO	SMA200	-6.45%	Avg Volume	721.31K	Price	37.85
IPO	Feb 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	1687.30% 4.56%	Trades		Volume	402,900	Change	-2.82%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Downgrade	BTIG Research	Buy → Neutral
Aug-09-24	Initiated	Canaccord Genuity	Buy	$57
Jun-20-24	Initiated	TD Cowen	Buy	$55
Jan-25-24	Upgrade	Truist	Hold → Buy	$39 → $51
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy	$39
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight	$40
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight	$31
Sep-17-20	Initiated	Truist	Buy	$24
Oct-09-19	Initiated	H.C. Wainwright	Buy	$19
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy	$15 → $14
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform	$15
Mar-06-18	Reiterated	Needham	Buy	$5 → $15
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-05-18	Reiterated	BTIG Research	Buy	$8 → $13
Jun-21-17	Initiated	BTIG Research	Buy	$6

Show Previous Ratings

Nov-14-25 08:30AM	Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025 (GlobeNewswire)
Nov-10-25 09:55AM	Wall Street Analysts Believe Vericel (VCEL) Could Rally 39.42%: Here's is How to Trade (Zacks)
Nov-06-25 04:01PM	Vericel Corp (VCEL) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
09:10AM	Vericel Corporation (VCEL) Q3 Earnings and Revenues Top Estimates (Zacks)
07:55AM	Vericel Reports Third Quarter 2025 Financial Results (GlobeNewswire)
09:15AM	Loading…
Oct-31-25 09:15AM	Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out? (Zacks)
Oct-23-25 08:30AM	Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-22-25 08:48AM	Here's Why Vericel Corporation (VCEL) Underperformed in Q3 (Insider Monkey)
Oct-20-25 11:08PM	Truist Lowers PT on Vericel Corporation (VCEL) to $41 From $46 (Insider Monkey)
Sep-12-25 08:53AM	Here's Why Vericel Corp. (VCEL) Traded Down in Q2 (Insider Monkey)
Sep-11-25 03:46PM	Is the Options Market Predicting a Spike in Vericel Stock? (Zacks) +7.09%
Aug-28-25 08:30AM	Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025 (GlobeNewswire)
Aug-20-25 12:13AM	Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating (Insider Monkey)
Jul-31-25 09:15AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -14.07%
08:08AM	Vericel Reports Second Quarter 2025 Financial Results (GlobeNewswire)
09:44AM	Loading…
Jul-30-25 09:44AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 Result (GuruFocus.com)
09:00AM	Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-24-25 09:47AM	Vericel Corporation (VCEL): A Bull Case Theory (Insider Monkey)
Jul-17-25 08:30AM	Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025 (GlobeNewswire)
Jun-10-25 08:30AM	Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025 (GlobeNewswire)
May-09-25 03:13AM	Vericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
May-08-25 09:05AM	Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:45AM	Vericel Corporation (VCEL): Among Stocks with Insanely High PE Ratios Insiders Are Selling (Insider Monkey)
07:55AM	Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance (GlobeNewswire)
May-07-25 02:18PM	Vericel Q1 2025 Earnings Preview (Seeking Alpha) +5.25%
10:08AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q1 2025 Result (GuruFocus.com)
08:30AM	Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 (GlobeNewswire)
May-06-25 05:35PM	Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
May-01-25 05:15PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-30-25 08:39AM	Vericel Corp. (VCEL) Faces Challenges as Burn Care Revenue Wanes and MACI Growth Remains Uncertain (Insider Monkey)
08:30AM	Loading…
Apr-24-25 08:30AM	Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Mar-04-25 08:30AM	Vericel to Present at Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-28-25 02:11AM	Vericel Corp (VCEL) Q4 2024 Earnings Call Highlights: Record Revenue and Strong Growth Trajectory (GuruFocus.com)
01:51AM	Q4 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:05AM	Vericel Corporation (VCEL) Tops Q4 Earnings Estimates (Zacks) -6.11%
07:54AM	Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 07:28AM	Earnings To Watch: Vericel Corp (VCEL) Reports Q4 2024 Result (GuruFocus.com)
Feb-13-25 08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Jan-14-25 04:05PM	Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets (GlobeNewswire)
Jan-08-25 08:30AM	Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 (GlobeNewswire)
Dec-19-24 07:36AM	Vericel price target raised to $67 from $61 at Truist (TipRanks)
Nov-11-24 02:06PM	Vericel Stock Sees RS Rating Shoot Higher (Investor's Business Daily) +5.15%
Nov-08-24 04:03AM	Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ... (GuruFocus.com) +7.94%
Nov-07-24 09:10AM	Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:55AM	Vericel Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 07:15AM	Vericel Corp (VCEL) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +7.35%
Oct-24-24 08:30AM	Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-22-24 09:31AM	Vericel Corp. (VCEL) Cooled Down in Q3 After a 20% Rise in the First Half (Insider Monkey)
Oct-18-24 03:04PM	State Street Corp's Strategic Reduction in Vericel Corp Holdings (GuruFocus.com)
Oct-09-24 03:44PM	Vericel Corp (VCEL) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
Aug-29-24 09:17AM	Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 (GlobeNewswire)
Aug-26-24 07:45AM	Vericel Announces FDA Approval and Commercial Availability of MACI Arthro (GlobeNewswire)
Aug-16-24 10:33AM	MediWound and Vericel win FDA paediatric label expansion for NexoBrid (Medical Device Network)
Aug-15-24 04:05PM	Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns (GlobeNewswire)
Aug-07-24 08:30AM	Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024 (GlobeNewswire)
Aug-05-24 12:00PM	What Makes Vericel (VCEL) a New Strong Buy Stock (Zacks)
Aug-01-24 09:05AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.94%
07:55AM	Vericel Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-29-24 03:45PM	AppFolio, Inc. (APPF): One of Ray Dalio's Top 10 Growth Stock Picks Right Now? (Insider Monkey)
Jul-22-24 08:30AM	Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer (GlobeNewswire)
Jul-18-24 08:30AM	Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jul-16-24 07:01PM	Insider Sale: CFO Mara Joseph Anthony Jr Sells 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jul-02-24 09:58AM	Should You Consider Adding Vericel Corporation (VCEL) to Your Portfolio? (Insider Monkey)
Jun-27-24 02:03PM	The 3 Highest-Rated Medical Stocks You Can Buy Today (InvestorPlace)
Jun-25-24 07:22AM	Factors Behind Vericel Corporation (VCEL) Stock's Positive Momentum (Insider Monkey)
Jun-20-24 09:54AM	Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls (The Fly)
Jun-11-24 08:30AM	Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 (GlobeNewswire)
May-22-24 08:30AM	Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 (GlobeNewswire)
May-21-24 06:42AM	Multiple Factors Pushed Vericel Corp. (VCEL) in Q1 (Insider Monkey)
May-09-24 03:28PM	Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:08AM	Vericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-08-24 11:24PM	Q1 2024 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Vericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core Markets (GuruFocus.com)
09:10AM	Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell (MT Newswires)
07:55AM	Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance (GlobeNewswire)
Apr-24-24 08:30AM	Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Mar-29-24 07:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
Mar-28-24 01:48PM	Land Developer And A Specialty Medical Stock Burst Into Buy Zones (Investor's Business Daily)
Mar-15-24 07:00PM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Mar-01-24 09:30AM	Vericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:37PM	Q4 2023 Vericel Corp Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Vericel Corporation (VCEL) Q4 Earnings Beat Estimates (Zacks)
08:32AM	Vericel Corp (VCEL) Reports Robust Revenue and EBITDA Growth in Q4 and Full-Year 2023 (GuruFocus.com)
07:55AM	Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance (GlobeNewswire)
Feb-27-24 08:30AM	Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 (GlobeNewswire)
Feb-22-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vericel Corporation (VCEL) is a Great Choice (Zacks)
Feb-18-24 03:00AM	Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares (GuruFocus.com)
Feb-15-24 10:00AM	Vericel Corporation (VCEL) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
08:50AM	Vericel Corporation (VCEL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
08:30AM	Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 08:30AM	Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024 (GlobeNewswire)
Jan-30-24 11:01PM	Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL) (GuruFocus.com)
08:50AM	Recent Price Trend in Vericel Corporation (VCEL) is Your Friend, Here's Why (Zacks)
Jan-25-24 09:49AM	Tesla, Boeing downgraded: Wall Street's top analyst calls (The Fly)
Jan-24-24 07:01PM	Director ZERBE ROBERT L MD Sells 8,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)
Jan-19-24 08:28PM	Vericel Corp President and CEO Dominick Colangelo Sells 33,452 Shares (GuruFocus.com) +5.95%
Jan-09-24 08:47AM	Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last? (Zacks) +7.24%
07:55AM	Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results (GlobeNewswire)
Jan-03-24 08:30AM	Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 (GlobeNewswire)
Dec-17-23 03:01AM	Insider Sell: Director Paul Wotton Offloads 5,000 Shares of Vericel Corp (VCEL) (GuruFocus.com)

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.